1Rose M;McMahon FG.Some problems with anti_ hypertensive drug studies in the context of the new guide line,1990.
2Giuseppe M;Daniele A;Gerard J.Effect of the converting enzyme inhibition benazepril on the pro_gression of chronic renal insufficiency[J],1996.
3Hollenberg NK;Adams DF.The renal circulation in hypertensive disease[J],1976.
4Valve E;Gammaro L;Bedogna V.Systemic and renal haemodynamic changes of two_months treatment with enalapril in patients with essential hypertension,1987.
5Richer C;Doussau MP;Giudicelli JF.Systemic and regional hemodynamic profile of five angiotensin_converting enzyme inhibitions in the spontaneously hypertensive rat[J],1987.
6Heeg JE;De Jong PE;Van der Hem GK.Reduction of proteinura by angiotensin_converting enzyme inhibition[J],1987.
7Dwokin L;Feinet HD;Randazzo J.Glomerular hy_ pertension and injury in the deoxycortcosterone_salt rats on antighpertensive therapy[J],1987.
8Bohrer MP;Deen WM;Robertson CR.Mecha_ nism of angiotensin Ⅱ _proteinuria in the rat,1977.
9Friedrich SP;Lorell BM;Rousseau MF.In_ tracardiac angiotensin_converting enzyme inhibition improves diastolic function in patients with left ven_ tricular hypertrophy due to aortic stenosis,1994(06).
10Haber HL;Powers ER;Gimpile LW.Intra_ coronary angiotensin_converting enzyme inhibition improves diastolic function in patients with hyper_ tension left ventricular hypertrophy,1994(06).
2NevilleF, KennethC, Lasseter, et al. Single-Dose and steady-state pharmacokinetics of Fosinopril and Fosinoprilat in patients with Hepatic Impairment[J]. J Clin Pharmacol,1995, 35:145-150.
4M Lomgardo M, Alli C, Broccolino et al. Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension[J]. Am Heart J, 1997, 134:557-564.
5Waldemar G, Ibsen H, Strandgaard S, et al. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension[J] Am J Hypertens, 1990, 3:464-470.
6Duchin KL, Waclawsk al. Pharmacokinetics pharmacologic effects sodium, an angioters enzyme inhibitor i AP, Tu JI,et , safety, and of fosinopril in-converting in health subjects[J]. J Clin Pharmacol, 1999, 31:58 - 64.
7Johnston C I. Angiotensin receptor antagonists: focus on losartan[J]. Lancet, 1995,346(8987):1403-1407.
8Mento P F, Wilkes B M. Plasma angiotensin and blood pressure during converting enzyme inhibition[J]. Hypertension, 1987,9(6 Pt2):Ⅲ42-48.
9Touyz R M, Endemann D, He G, et al. Role of AT2 receptors in angiotensin Ⅱ-stimulated contraction of small mesenteric arteries in young SHR[J]. Hypertens, 1999,33(1Part Ⅱ):366-372.
10Ji H, Leung M, Zhang Y, et al. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor: identification of amino acid residues that determine binding of the antihypertensive drug losartan[J]. J Biol Chem, 1994,269(24):16533-16536.
